Publications: DR Sean Carlson

Roberts C, Peters J, Sazonvos A, Goodman N, Sharip M, Smith R, Bishara M, Bewshea C et al. ( 2025 ) . Clinical Utility and Cost‐Effectiveness of Pretreatment <i>NUDT15</i> Pharmacogenetic Testing to Prevent Thiopurine‐Induced Myelosuppression: A Genotype‐First Reverse Phenotyping Cohort Study Within the <scp>UK NIHR</scp> Inflammatory Bowel Disease Bioresource . Alimentary Pharmacology &amp; Therapeutics Article apt.70232 ,

Mathew L, Carlson S, Savage M, Pardieu C, Sze N, Munro C, Naglik J, Stagg A et al. ( 2024 ) . P145 Phagocyte responses to gut-derived C. albicans are modified in inflammatory bowel disease . Journal of Crohn's and Colitis vol. 18 , ( Supplement_1 ) i441 - i441 .

Carlson SL, Mathew L, Savage M, Kok K, Lindsay JO, Munro CA, McCarthy NE ( 2023 ) . Mucosal Immunity to Gut Fungi in Health and Inflammatory Bowel Disease . Journal of Fungi vol. 9 , ( 11 ) 1105 - 1105 .

Chanchlani N, Lin S, Auth MK, Lee CL, Robbins H, Looi S, Murugesan SV, Riley T et al. ( 2022 ) . Implications for sequencing of biologic therapy and choice of second <scp>anti‐TNF</scp> in patients with inflammatory bowel disease: results from the <scp>IMmunogenicity</scp> to Second <scp>Anti‐TNF</scp> therapy (<scp>IMSAT</scp>) therapeutic drug monitoring study . Alimentary Pharmacology &amp; Therapeutics vol. 56 , ( 8 ) 1250 - 1263 .